Business
Special Committee of Cipher Pharmaceuticals Responds to Early Warning Report Filed by 1207407 Ontario Limited
Special Committee of Cipher Pharmaceuticals Responds to Early Warning Report Filed by 1207...
About this update from Cipher Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nSpecial Committee of Cipher Pharmaceuticals Responds to Early Warning Report Filed by 1207407 Ontario Limited\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nSpecial Committee of Cipher Pharmaceuticals Responds to Early Warning Report Filed by 1207407 Ontario Limited\nCanada NewsWire\nMISSISSAUGA, ON, July 6, 2016\n\n\n\nMISSISSAUGA, ON, July 6, 2016 /CNW/ - A special committee (the \"Special Committee\") of the board of directors (the \"Board\") of Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) (\"Cipher\") responded today to an Early Warning Report (the \"EWR\") filed on July 5, 2016 by 1207407 Ontario Limited (\"1207407\"), a company wholly owned by Dr. John D. Mull.  The Special Committee, comprised of directors Stephen Wiseman, Thomas Wellner, William Claypool and Stefan Aigner, was established to address issues of the type referred to in the EWR.\n\nCipher welcomes the opinions of its shareholders and actively seeks opportunities to enhance shareholder value. The Board takes its fiduciary responsibilities seriously. The Special Committee is disappointed that Dr. Mull has chosen to use a public forum to claim ownership of a series of initiatives, many of which were already under active ongoing discussion by the members of the Board, including Dr. Mull. The directors of Cipher share many of the concerns enumerated in the EWR, and have proactively sought to address those concerns, including through the formation of the Special Committee.\n\nThe Special Committee and the Board will continue to meet to consider further steps to advance the evaluation of initiatives.\n\nAbout Cipher Pharmaceuticals Inc.\n\nCipher Pharmaceuticals (NASDAQ:CPHR; TSX:CPH) is a rapidly growing specialty pharmaceutical dermatology company with a diversified portfolio of commercial-stage products with the goal of becoming the most customer-centric dermatology company in North America.\n\nThrough multiple transactions, including the acquisition of Innocutis and its nine branded dermatology products, Cipher has built its U.S. commercial presence, expanded its ...